The cellular electrophysiological effects of 1 PM tedisamil (KC 8857) were studied in human atria1 and ventricular fibers. Conventional microelectrode technique was applied to record the transmembrane action potentials at stimulation frequency of 100 per min and 37°C. Tedisamil lengthened action potential duration (APD) more in atria1 than in ventricular muscle fibers; prolongation of APD, was 28.9 f 3.3% (n = 6; p < 0.05) for atria1 and 13.3 f 5.2% (n -6; P < 0.05) for venticular tissue. The maximal rate of depolarization was depressed slightly, but significantly by 1 PM tedisamil only in ventricular fibers (12.9 + 6.5%, n = 6, P < 0.05). From these cellular electrophysiological data it is concluded that the bradycardic/antiischemic agent tedisamil possesses marked Class III properties not only in cardiac tissues of experimental animals but also those of man.
Introduction
In the last two decades a large number of new antiarrhythmic drugs has been introduced into therapy. Many of them significantly impaired conduction at normal heart rate with little effect on repolarization (Class IC). These drugs were very potent in suppressing PVCs (premature ventricular contractions) which is considered an important risk factor for initiating ventricular fibrillation and consequently sudden arrhythmic death [ll. However, the recent CAST trials [1, 2] proved that Class IC drugs, instead of decreasing, rather increased mortality in patients [ 1, 2] . As an immediate consequence, the CAST studies rapidly shifted the interest toward drugs which do not interfere with conduction but increase action potential duration (APD) and, as a result, the effective refractory period (ERP) (Class III drugs), terminating reentry arrhythmias by this means. Tedisamil (KC8857), a new bradycardic antiis- chemic agent is such a new compound which exerts Class III actions [3-61 in experimental animals, such as rats and guinea pigs. Although the major ionic currents underlying the cardiac action potentials described in animals have also been identified in humans [7] , it is still often misleading to extrapolate experimental cardiac electrophysiological results obtained in animal models to man. Therefore, in the present study we investigated the cellular electrophysiological effects of tedisamil in human atria1 and ventricular tissue.
Methods
Atria1 and ventricular muscle preparations were obtained from hearts of 11 patients (age: 2-64 years) with various clinical diagnoses (pulmonary stenosis, mitral stenosis, Fallot tetralogy) undergoing open heart surgery. After surgical excision the tissues were immediately rinsed in cold oxygenated Tyrode's solution containing (in mM): Na+ 140, K+ 4, Ca2' 2. when gassed with 95% 0, and 5% CO, at 37°C. The preparations were individually mounted in a tissue chamber (volume w 50 ml). Each preparation was initially stimulated (HSE Stimulator Type 215/11.) at a basic cycle length of 600 ms (frequency = lOO/min), using 2 ms long rectangular constant current pulses. The current pulses were isolated from the ground across bipolar platinum electrodes in contact with the preparation. At least one hour was allowed for each preparation to equilibrate while they were continuously superfused with Tyrode's solution.
The temperature was kept constant at 37°C. 
Results
The effects of tedisamil on the action potential parameters in human atria1 and ventricular muscle are summarized in Table 1 and illustrated in Fig. 1 . Tedisamil (1 PM) significantly increased the APD, in both atria1 and ventricular muscle without considerably altering RP and APA. The lengthening of repolarization was more pronounced in atria1 than in ventricular muscle (28.9 f 3.3% n = 6; vs. 13.3 f 5.2% n = 6, P < 0.05). Furthermore, in atria1 muscle, after superfusion with 1 PM tedisamil, the prolongation of APD,, was found statistically significant, but in ventricular muscle it did not change considerably. In ventricular muscle 1 PM tedisamil slightly but significantly depressed VmaX. In atria1 tissue however, at the same stimulation frequency (lOO/min), the Vm, was not considerably affected by the drug.
Discussion
The resting membrane potential (RP), action potential amplitude (APA), action potential durations measured at 50 and 90% of repolarization (APD,,-,,)
were obtained using software (developed in our institution by Otto HGla) with a 386 IBM compatible computer connected to the digital output of the oscilloscope.
The preparations had been superfused for 30 min with 1 PM tedisamil before measurements were started. Whenever it was possible, the same impalement was maintained throughout the experiment. When impalement was lost during measurement, readjustment was attempted. If the readjusted parameters were deviant not more than 10% from the previous ones, experiments were continued, otherwise they were terminated.
Student's test for paired and unpaired data were used to compare the results statistically. Results were considered significant when P was found to be less than 0.05.
The results of the present study provide evidence that tedisamil lengthens repolarization in human atria1 and ventricular muscle. This observation agrees with previous findings in animal and very recent human experiments. In guinea pig papillary muscle moderate prolongation of the APD without effect on \imaX has been observed with 1 PM tedisamil [5] . In rat and human ventricular muscle, however, a marked lengthening of repolarization was described [6, 8] . In the same experiments tedisamil speeded up inactivation of the transient outward current (I,), thereby decreasing the density of this current [6] . I,, is generally considered an important repolarizing current in rat and human ventricular muscle and in atria1 muscle from several species [9-l 11, including humans [lo] . Tedisamil has been found to depress the delayed rectifier outward potassium current (I,) in guinea pig ventricular myocytes [6] with a Kd of 2.5 PM, while the inward sodium current has been found to decrease only in concentrations higher than Table 1 The effects of tedisamil on the action potential parameters in human atria1 and ventricular fibers at lOO/min stimulation frequency =w RP (mV) APA ( 20 PM. The effect of tedisamil on the APD in our study can be best explained by its depressant effects on I, and I,. In the present experiments tedisamil slightly but significantly decreased v,,,,, in ventricular muscle but not in atria1 fibers at cycle length of 600 ms. One may speculate that tedisamil preferably blocks inactivated sodium channels with relatively fast recovery kinetics like lidocaine [12] . Should this be the case in atria1 cells, which have shorter plateau duration than ventricular cells, less qmX block can be expected to develop during the action potential. Postulating the fast recovery kinetics, the developed ?nax block would dissipate largely during the diastole at cycle length of 600 ms. In summary, we conclude that in human atria1 and ventricular muscle tedisamil is capable of increasing APD with concomitant slight depression of '?,,,,,. Our findings supplement the existing in vivo and in vitro mammalian electrophysiological results [5, 6] with human data and confirm that tedisamil shows Class III effects in addition to its bradycardic/antiischemic properties.
